Literature DB >> 35767079

A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study.

Takayuki Arai1, Tomokazu Sazuka2, Hiroaki Sato1, Mayuko Kato1, Shuhei Kamada1, Sota Katsura1, Ayako Seito1, Shu Miyamoto1, Ken Wakai1, Nobuyoshi Takeuchi1, Yusuke Imamura1, Shinichi Sakamoto1, Akira Komiya1, Tomohiko Ichikawa1.   

Abstract

BACKGROUND: Late recurrence of renal cell carcinoma (RCC) is observed in some postoperative patients. In addition, some of these patients are lost to long-term postoperative follow-up. We reviewed the treatment results and prognosis of postoperative patients with RCC at Chiba University Hospital, with the aim of clarifying the proportion and background of patients lost to follow-up.
METHODS: This retrospective study included 1176 RCC patients who underwent radical or/and partial nephrectomy. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and lost follow-up free survival (LFFS) were evaluated and the risk factors for LFFS identified.
RESULTS: The median RFS for stage II and II cases was 188.3 and 104.0 months, respectively. Even in stage I, recurrence was observed in about 20% of patients 20 years after surgery. The Kaplan-Meier curve for LFFS showed a linear descent over time, with 50% of patients lost to follow-up within 25 years. Older age (≥ 62 years), histological type (clear cell RCC), and no recurrence were significant risk factors for lost follow-up.
CONCLUSIONS: Long-term follow-up is necessary after RCC surgery because late recurrence cases are not uncommon. We believe that lifelong follow-up with imaging studies is recommended for postoperative RCC patients. Early detection of recurrence in postoperative patients is a very important issue, and it may be worthwhile for improving the prognosis of postoperative patients to focus on patients lost to follow-up who may have been overlooked.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Lost follow-up free survival; Nephrectomy; Postoperative; Recurrence; Renal cell carcinoma

Mesh:

Year:  2022        PMID: 35767079     DOI: 10.1007/s10147-022-02204-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.850


  19 in total

1.  Long-Term Functional and Oncologic Outcomes of Robot-Assisted Partial Nephrectomy for Cystic Renal Tumors: A Single-Center Retrospective Study.

Authors:  Kenji Zennami; Kiyoshi Takahara; Ryo Matsukiyo; Takuhisa Nukaya; Masashi Takenaka; Kosuke Fukaya; Manabu Ichino; Naohiko Fukami; Hitomi Sasaki; Mamoru Kusaka; Hiroshi Toyama; Makoto Sumitomo; Ryoichi Shiroki
Journal:  J Endourol       Date:  2021-01-06       Impact factor: 2.942

2.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Authors:  Robert J Motzer; Brian I Rini; David F McDermott; Osvaldo Arén Frontera; Hans J Hammers; Michael A Carducci; Pamela Salman; Bernard Escudier; Benoit Beuselinck; Asim Amin; Camillo Porta; Saby George; Victoria Neiman; Sergio Bracarda; Scott S Tykodi; Philippe Barthélémy; Raya Leibowitz-Amit; Elizabeth R Plimack; Sjoukje F Oosting; Bruce Redman; Bohuslav Melichar; Thomas Powles; Paul Nathan; Stéphane Oudard; David Pook; Toni K Choueiri; Frede Donskov; Marc-Oliver Grimm; Howard Gurney; Daniel Y C Heng; Christian K Kollmannsberger; Michael R Harrison; Yoshihiko Tomita; Ignacio Duran; Viktor Grünwald; M Brent McHenry; Sabeen Mekan; Nizar M Tannir
Journal:  Lancet Oncol       Date:  2019-08-16       Impact factor: 41.316

3.  Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy.

Authors:  Sebastian K Frees; Mohammed M Kamal; Sebastian Nestler; Patrick Mf Levien; Samir Bidnur; Walburgis Brenner; Christian Thomas; Wolfgang Jaeger; Joachim W Thüroff; Frederik C Roos
Journal:  Int J Urol       Date:  2018-12-26       Impact factor: 3.369

4.  Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach.

Authors:  Suzanne B Stewart-Merrill; R Houston Thompson; Stephen A Boorjian; Sarah P Psutka; Christine M Lohse; John C Cheville; Bradley C Leibovich; Igor Frank
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable.

Authors:  Tetsuya Shindo; Naoya Masumori; Ko Kobayashi; Fumimasa Fukuta; Megumi Hirobe; Akiko Tonooka; Tadashi Hasegawa; Hiroshi Kitamura; Taiji Tsukamoto
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

Review 7.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

8.  Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002.

Authors:  Ken Marumo; Hiroomi Kanayama; Noriomi Miyao; Hayakazu Nakazawa; Seiichiro Ozono; Shigeo Horie; Satoshi Nagamori; Tatsuo Igarashi; Michihiko Hasegawa; Go Kimura; Masahiro Nakao; Takahisa Nakamoto; Seiji Naito
Journal:  Int J Urol       Date:  2007-06       Impact factor: 3.369

9.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

10.  A Retrospective, Multicenter, Long-Term Follow-Up Analysis of the Prognostic Characteristics of Recurring Non-Metastatic Renal Cell Carcinoma After Partial or Radical Nephrectomy.

Authors:  Sung Han Kim; Boram Park; Eu Chang Hwang; Sung-Hoo Hong; Chang Wook Jeong; Cheol Kwak; Seok Soo Byun; Jinsoo Chung
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.